Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Citation: Boominathan, L., MiRNA-based Lifespan extension therapy: MiRNA-138 promotes mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 5/June/2014, 7.49 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com
Significance: It has been shown earlier that angiotensin II type I receptor (AT1R) antagonist prolongs mammalian life span. This study suggests, for the first time, that MiRNA-138, by decreasing the expression of its target gene, it may suppress the expression of AT1R. And, thereby, it may (1) decrease blood pressure; and (2) and extend the lifespan of an individual. Thus, pharmacological formulations encompassing “MiRNA-138 activators“ may be used to extend the life-span of an individual.
Undisclosed information: How MiRNA-138 suppresses the expression of angiotensin II type I receptor (AT1R)
# Research cooperation